Given its multifaceted role in promoting radioresistance, TGF-β is being explored as a therapeutic target in combination with SBRT, particularly in tumors with baseline high TGF-β activity, such as pancreatic cancer [25,28]. This evidence concerns the gene TGFB1 and familial pancreatic carcinoma.